Modeling and Simulation Archives

Fact Sheet

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…

CertaraFebruary 19, 2025

Video

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Today’s drug candidates are more complex than ever. But with development decisions on the line,…

CertaraFebruary 12, 2025

Poster

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

CertaraFebruary 7, 2025

On-Demand Webinar

Machine Learning for Population PK Model Selection: Theory and Practice

Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…

CertaraFebruary 7, 2025

On-Demand Webinar

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…

CertaraFebruary 7, 2025

Publication

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

CertaraFebruary 6, 2025

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

CertaraJanuary 23, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Press Coverage

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…

CertaraDecember 24, 2024

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

CertaraDecember 11, 2024

Modeling and Simulation

Pharmacometrics Drug Development Decision Support: Model-Based Meta-Analysis (MBMA)

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Machine Learning for Population PK Model Selection: Theory and Practice

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Understanding Variability in CAR-T Cell Therapy Kinetics

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Newsletter sign up

Quick links

Solutions

Contact